Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor

被引:1
|
作者
Rakotoambinina, B
Médioni, J
Rabian, C
Jubault, V
Jais, JP
Viard, JP
机构
[1] Hop Necker Enfants Malad, Serv Immunol Clin, F-75743 Paris 15, France
[2] Hop Necker Enfants Malad, Dept Biostat, F-75743 Paris 15, France
关键词
lipodystrophy; protease inhibitors; nucleoside analogs; hyperlipidemia; HIV infection;
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: To assess the frequency and features of lipodystrophic syndromes in HIV-1-infected patients receiving highly active antiretroviral therapy (HAART) with a protease inhibitor (PI), and examine whether clinical and biologic abnormalities are always associated in these conditions. Methods: Retrospective-prospective single-center observational study of 175 patients. Comparisons for continuous variables by t-test and paired t-test, and Kaplan-Meier analysis of time to onset of lipodystrophy were performed. Results: In all, 51 patients (29%) had morphologic changes, after a mean HAART duration of 20.0 +/- 6.1 months, and were categorized into pure lipoatrophy (n = 16), mixed syndrome (truncal fat accumulation and face or limb lipoatrophy) (n = 30) or pure truncal fat accumulation (In = 5). Because of the small number, the latter group was not analyzed statistically. No differences were found among patients with lipoatrophy, mixed syndrome, or no lipodystrophy, in terms of gender, CD4 count, and HIV RNA plasma load at time of HAART initiation, nor in response to treatment. Patients with a mixed syndrome were older. Patients with lipoatrophy had longer duration of HIV disease, pre-HAART exposure to nucleoside analog therapy, and HAART. Baseline and pre-HAART fasting triglyceride levels were higher in patients who developed lipoatrophy, whereas weight and fasting cholesterol were higher in patients who developed a mixed syndrome. After 12 and 24 months on HAART, triglycerides and cholesterol rose significantly in all patients, independently of lipodystrophy, whereas these parameters were not increased during nucleoside analog therapy. Conclusions: Nucleoside analog exposure appears as a risk factor for lipoatrophy. Age and nutritional status (reflected by baseline weight, triglycerides and cholesterol) may influence the evolution to lipoatrophy or a mixed syndrome. Hyperlipidemia is observed in the absence of lipodystrophy and depends on PI exposure.
引用
收藏
页码:443 / 449
页数:7
相关论文
共 50 条
  • [1] Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia
    Lu, Ching-Lan
    Lin, Yu-Hui
    Wong, Wing-Wai
    Lin, Hsi-Hsin
    Ho, Mao-Wang
    Wang, Ning-Chi
    Hsieh, Szu-Min
    Sheng, Wang-Huei
    Hung, Chien-Ching
    Chen, Mao-Yuan
    JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2011, 44 (04) : 258 - 264
  • [2] Response to two consecutive protease inhibitor combination therapy regimens in a cohort of HIV-1-infected children
    Palacios, GC
    Palafox, VL
    Alvarez-Muñoz, MT
    Vazquez, G
    Miranda, G
    Muñoz, O
    Solorzano, F
    SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2002, 34 (01) : 41 - 44
  • [3] Prevalence of chronic kidney disease among HIV-1-infected patients receiving a combination antiretroviral therapy
    Leonardo Calza
    Michele Sachs
    Vincenzo Colangeli
    Marco Borderi
    Bianca Granozzi
    Pietro Malosso
    Giorgia Comai
    Valeria Corradetti
    Gaetano La Manna
    Pierluigi Viale
    Clinical and Experimental Nephrology, 2019, 23 : 1272 - 1279
  • [4] Prevalence of chronic kidney disease among HIV-1-infected patients receiving a combination antiretroviral therapy
    Calza, Leonardo
    Sachs, Michele
    Colangeli, Vincenzo
    Borderi, Marco
    Granozzi, Bianca
    Malosso, Pietro
    Comai, Giorgia
    Corradetti, Valeria
    La Manna, Gaetano
    Viale, Pierluigi
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2019, 23 (11) : 1272 - 1279
  • [5] Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy
    Calza, L
    Manfredi, R
    Farneti, B
    Chiodo, F
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2003, 22 (01) : 54 - 59
  • [6] Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy
    Martínez, E
    Blanco, JL
    Arnaiz, JA
    Pérez-Cuevas, JB
    Mocroft, A
    Cruceta, A
    Marcos, MA
    Milinkovic, A
    García-Viejo, MA
    Mallolas, J
    Carné, X
    Phillips, A
    Gatell, JM
    AIDS, 2001, 15 (10) : 1261 - 1268
  • [7] Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy
    Koppel, K
    Bratt, G
    Schulman, S
    Bylund, H
    Sandström, E
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2002, 29 (05) : 441 - 449
  • [8] No correlation between statin exposure and incident diabetes mellitus in HIV-1-infected patients receiving combination antiretroviral therapy
    Calza, L.
    Colangeli, V.
    Magistrelli, E.
    Manfredi, R.
    Bon, I.
    Re, M. C.
    Viale, P.
    HIV MEDICINE, 2016, 17 (08) : 631 - 633
  • [9] Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy
    Aleman, S
    Söderbärg, K
    Visco-Comandini, U
    Sitbon, G
    Sönnerborg, A
    AIDS, 2002, 16 (07) : 1039 - 1044
  • [10] Creatine kinase elevation in HIV-1-infected patients receiving raltegravir-containing antiretroviral therapy: a cohort study
    Monteiro, Polyana
    Perez, Inaki
    Pich, Judit
    Maria Gatell, Jose
    Martinez, Esteban
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2013, 68 (02) : 404 - 408